Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. News related to Oragenics often centers on the progress of its lead intranasal drug candidate, ONP-002, which is being advanced for the treatment of concussion and mild traumatic brain injury, as well as broader developments in its intranasal platform for neurological disorders.
Investors and followers of OGEN can use this news feed to track company announcements about clinical milestones, such as Human Research Ethics Committee approval in Australia, selection of Southern Star Research as Clinical Research Organization for the Phase IIa ONP-002 trial, and updates on anticipated Phase IIa and Phase IIb studies. Oragenics’ press releases also cover manufacturing and operational agreements, including its cGMP production partnership with Sterling Pharma Solutions to supply ONP-002 for clinical development.
Another recurring theme in Oragenics news is strategic and financial activity. The company has reported public offerings of Series H Convertible Preferred Stock and Warrants, at-the-market equity sales, and related steps taken to restore and maintain compliance with NYSE American stockholders’ equity requirements. These updates provide context on how Oragenics is funding its clinical programs and strengthening its balance sheet.
In addition, Oragenics issues news about pipeline expansion and partnerships, including its collaboration with Receptor.AI, an artificial intelligence–driven drug profiling company, aimed at accelerating development of additional pharmaceutical candidates for brain health. The company also announces its participation in industry conferences and investor events, where it presents its intranasal concussion program and broader neurological platform. Readers interested in OGEN can follow this page for ongoing disclosures directly sourced from company press releases and related regulatory communications.
Oragenics (NYSE American: OGEN) announced receipt of an unqualified audit opinion on its consolidated financial statements, which included an explanatory paragraph about the Company’s ability to continue as a going concern. The Form 10-K for the year ended December 31, 2025 was filed March 16, 2026.
The announcement complies with NYSE American Company Guide Section 610(b) and does not amend or change the audited financial statements; supporting detail appears in footnote 1 of the 2025 consolidated financial statements. The 10-K is available on the SEC EDGAR system and the company’s investor relations website.
Oragenics (NYSE American: OGEN) filed its Form 10-K for the fiscal year ended December 31, 2025 and provided a shareholder update on 2025 milestones and Q1 2026 progress.
Key 2025 highlights include a $16.5 million capital raise, repayment of a $3.0 million promissory note, an 11% reduction in operating expenses, US cGMP manufacturing engagement, CRO contracting for a Phase IIa trial, and a partnership with Receptor.AI. Q1 2026 updates include HREC approval in Australia, initial site initiation visit, and IND readiness work with DUCK FLATS Pharma.
Oragenics (NYSE American: OGEN) completed the first site initiation visit for its Phase IIa trial of ONP-002 in Australia on March 12, 2026.
First SIV finished at one of three planned Australian sites; two remaining sites are completing Research Governance Office reviews after Human Research Ethics Committee approval. The randomized, placebo-controlled trial targets 40 patients, dosing within 12 hours of concussion onset, with primary endpoints around safety, neurocognitive assessments, and tolerability.
Oragenics (NYSE American: OGEN) is exploring acquisition of CNS assets focused on brain health and brain recovery to complement its intranasal delivery platform and lead candidate ONP-002.
ONP-002 Phase IIa is in active site initiation in Australia; Phase 1 showed safety in 40 patients with zero serious adverse events. No definitive acquisition agreements have been reached; any material transaction will be disclosed as required.
Oragenics (NYSE: OGEN) received final Human Research Ethics Committee (HREC) approval in Australia to begin a randomized, placebo-controlled Phase IIa trial of ONP-002 for concussion/mild traumatic brain injury. The trial will enroll 40 patients across three Australian sites, with first dosing expected before the end of March 2026 and a data readout projected before year-end 2026. Patients will receive first dosing within 12 hours of injury and up to 30 days of treatment; the company cites a Phase 1 safety profile with zero serious adverse events. Trial management is expected to be handled by Southern Star Research.
Oragenics (NYSE American: OGEN) previewed 2026 milestones for ONP-002, a first-in-class intranasal neurosteroid targeting concussion and mild traumatic brain injury (mTBI). The company says it has a fully funded Phase 2a trial (40 patients) with U.S. cGMP manufacturing, a CRO selection, a strategic AI collaboration, and $16.5 million raised.
Near-term goals include Australian site onboarding, first patient dosing, interim data during 2026, a Q4 2026 final readout, and an FDA IND submission for U.S. trials.
Oragenics (NYSE American: OGEN) engaged DUCK FLATS Pharma as its U.S. IND readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design for its intranasal concussion therapy ONP-002.
The engagement aims to align an upcoming Phase 2a trial in Australia with U.S. regulatory strategy, leverage DUCK FLATS’ ~38 years of experience and prior roles on ~40 drug programs and >60 FDA-approved NDAs, and help advance ONP-002 toward a U.S. Phase 2b trial and later-stage development. The release cites a projected global concussion market >$9B by 2027 and a nasal drug delivery market >$125B by 2030.
Oragenics (NYSE American: OGEN) will participate in the SCOPE Summit 2026, Feb 2–5 in Orlando, engaging clinical operations leaders ahead of its planned Phase 2a trial of an intranasal concussion therapeutic in Australia.
The company highlighted its lead candidate ONP-002 and its intranasal delivery platform aimed at targeted, non‑invasive brain delivery for concussion and mild TBI.
Oragenics (NYSE American: OGEN) will present at the Sequire Investor Summit 2026 in San Juan, Puerto Rico, January 20-22, 2026.
The presentation will cover Oragenics' ONP-002 clinical program targeting concussion and mild traumatic brain injury and the company’s plan to advance ONP-002 into Phase 2a studies. The event is hosted at the Condado Vanderbilt Hotel; investors should review the summit agenda for the exact date and time of Oragenics’ session. For registration and conference details, visit the official event website.
Oragenics (NYSE American: OGEN) reported Q3 2025 operational, strategic, and financial milestones as it prepares for Phase IIa clinical work in Australia with anticipated initiation in Q4 2025–Q1 2026. Key achievements include regaining NYSE American compliance on Oct 20, 2025, completing a $16.5M gross capital raise (net proceeds ~$15.2M), eliminating a $3M note payable, securing HREC approval earlier in 2025 with amendments under review, appointing Southern Star Research as CRO, and contracting Sterling Pharma Solutions for cGMP manufacturing. The company also announced a strategic AI collaboration with Receptor.AI to accelerate its molecule pipeline beyond ONP-002 and reported year-to-date R&D expense reduction of 30%.